vidarabine phosphate and Primary Myelofibrosis

vidarabine phosphate has been researched along with Primary Myelofibrosis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Afkhami, M; Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Cao, T; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Nakamura, R; O'Donnell, M; Pillai, R; Pullarkat, V; Salhotra, A; Snyder, D; Stein, AS; Yang, D; Yang, L	1

Other Studies

1 other study(ies) available for vidarabine phosphate and Primary Myelofibrosis

Article	Year
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. Blood advances, 2019, 01-08, Volume: 3, Issue:1 Topics: Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Mutation; Primary Myelofibrosis; Prognosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine Phosphate	2019

Article

Year

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Blood advances, 2019, 01-08, Volume: 3, Issue:1

Topics: Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Mutation; Primary Myelofibrosis; Prognosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine Phosphate

2019